PGN-EDODM1 is under clinical development by Pepgen and currently in Phase I for Myotonic Dystrophy. According to GlobalData ... therapeutics for the treatment of severe neuromuscular and neurologic ...
Other symptoms may include: Often children with Becker muscular dystrophy can walk. As they get older they may need to use a cane or wheelchair to get around. The symptoms of myotonic dystrophy ...
Muscular dystrophy can appear in infancy up to middle ... to confirm the diagnosis or rule out another muscle disease. Neurological tests. Various tests are done to check nervous system function ...
ATLANTA--(BUSINESS WIRE)--$ABBV #ALZN--Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), a clinical-stage biopharmaceutical company, focused on developing novel ...
as well as SAGE-324 in essential tremor and other neurological disorders. The blockbuster deal featured an upfront payment of $875 million from Biogen and a $650 million equity investment in Sage.
Dyne Therapeutics touted an early-stage study of its RNA treatment for myotonic dystrophy type 1 and has selected the dose it plans to move forward … ...
(RTTNews) - Dyne Therapeutics, Inc. (DYN) Friday announced encouraging data from its ongoing Phase 1/2 ACHIEVE trial of DYNE-101 in patients with myotonic dystrophy type 1 (DM1). Myotonic ...
More information can be found on the page Qualifying exams. During exam registration you can allocate performance assessments to a certain CATEGORY of your study regulation. This allocation can still ...
Introduction: Myotonic dystrophy type 1 (DM1 ... Method: Twenty genetically verified DM1 patients were included. Pain was assessed, and neurological examination and investigations of the peripheral ...
Please note that if you are taking a module outside of your Part your exam may fall outside of the dates above. If you are taking a module (with an exam) from outside of your Part, the exam will be ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback